LEXINGTON, Mass., Jan. 13, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that a new article supporting the use of T2MR^® as a nanotechnology-based platform with the potential to significantly impact the field of diagnostics was published online today in The Journal of the American Medical Association (JAMA). The article, titled, "Nanotechnology," was co-authored by T2 Biosystems' Co-Founders Robert S. Langer, Sc.D., David H. Koch Institute Professor at the Massachusetts Institute of Technology and Ralph Weissleder, M.D., Ph.D., Thrall Professor of Radiology and Professor of Systems Biology at Harvard Medical School and Director of the Center for Systems Biology at Massachusetts General Hospital.

"One of the central challenges physicians face today in treating patients suspected of certain infections is the amount of time required to obtain diagnostic results in order to accurately treat that patient," said Dr. Langer. "Novel approaches such as T2MR represent an exciting advance over current diagnostic methodologies by providing test results in a matter of hours instead of days and without the need for blood culture, sample purification or preparation. With these earlier disease detection tools, physicians have the opportunity to significantly improve how they direct patients toward the most effective therapy, potentially lowering costs and saving lives."

The T2Candida^® Panel and the T2Dx^® Instrument are the first diagnostic products powered by T2MR, an innovative and proprietary magnetic resonance-based diagnostic technology platform. In September 2014, the U.S. Food and Drug Administrationcleared these products for use for the direct detection of Candida species in whole blood specimens from patients with symptoms of, or medical conditions predisposing the patient to, invasive fungal infections. Candida is the most lethal form of common bloodstream infections that cause sepsis, a life-threatening illness in which the body has a severe, inflammatory response to a bacterial or fungal infection. T2Candida and T2Dx are designed to detect Candida species directly from a whole blood specimen in three to five hours, compared to traditional blood culture, which can take two to six days or more to deliver results.

"We are very pleased to see this paper published in JAMA, which reinforces the T2MR platform as a rapid, sensitive and simple alternative to traditional diagnostic methodologies," said John McDonough, president and CEO of T2 Biosystems. "We believe our proprietary technology has the opportunity to make a significant impact on the way physicians are able to diagnose and treat bloodstream infections, and we are encouraged to see its inclusion in this insightful commentary from two visionary health care leaders."

The JAMA paper was published today online at http://jama.jamanetwork.com/journal.aspx, and will appear in an upcoming print edition of the journal.

About T2 Biosystems

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's final prospectus filed with the Securities and Exchange Commission, pursuant to Rule 424(b) of the Securities Act of 1933, as amended, on August 7, 2014, and in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2014, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

CONTACT: Media Contact:
         Susan Heins, Pure Communicationssjheins@purecommunicationsinc.com
         864-286-9597

         Investor Contact:
         Matt Clawson, Pure Communicationsmatt@purecommunicationsinc.com
         949-370-8500